A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Accessible Hot Air Ballooning
Tracey and Ian Gale recently took to the skies, trying out accessible hot air ballooning and ticking a memorable item off Ian’s Bucket List! “I wanted...
National Volunteer Week 2026
For National Volunteer Week 2026, we'd like to shine the spotlight on everyone who gives us their time and effort to help us support people living wit...
Brad and Carol's MND Story
In early 2025, Brad Lynch received his motor neurone disease (MND) diagnosis. He’d already been through months of tests, told he likely had other cond...
Top 5 Frequently Asked Questions from April 2026
Each month the MND InfoLine receives a wide range of enquiries from people living with MND, their families, and health professionals. We have rounded...